Resected lung cancer xenografts from this study provided information on how the antagonist repressed important molecular pathways, including ERK1/2 and AKT pathways as well as the expression of NF-κB p65 and vascular endothelial growth factor (VEGF). The gene discussed is AKT1; the disease is lung cancer.